242 related articles for article (PubMed ID: 34442408)
1. Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies.
Lewis KL; Cheah CY
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442408
[TBL] [Abstract][Full Text] [Related]
2. Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Campbell R; Chong G; Hawkes EA
J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29561760
[TBL] [Abstract][Full Text] [Related]
3. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
[TBL] [Abstract][Full Text] [Related]
4. Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.
Najmi A; Thangavel N; Mohanan AT; Qadri M; Albratty M; Ashraf SE; Saleh SF; Nayeem M; Mohan S
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986499
[TBL] [Abstract][Full Text] [Related]
5. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE; Wales TE; Jayne S; Britton RG; Fulton DB; Engen JR; Dyer MJS; Andreotti AH
bioRxiv; 2023 Dec; ():. PubMed ID: 38187560
[TBL] [Abstract][Full Text] [Related]
6. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
Garg N; Padron EJ; Rammohan KW; Goodman CF
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458
[TBL] [Abstract][Full Text] [Related]
7. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
Visentin A; Puthenparampil M; Briani C
Expert Opin Investig Drugs; 2023; 32(12):1105-1111. PubMed ID: 38153100
[TBL] [Abstract][Full Text] [Related]
8. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
9. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
10. The potential of pirtobrutinib in multiple B-cell malignancies.
Jensen JL; Mato AR; Pena C; Roeker LE; Coombs CC
Ther Adv Hematol; 2022; 13():20406207221101697. PubMed ID: 35747462
[TBL] [Abstract][Full Text] [Related]
11. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
von Hundelshausen P; Siess W
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806595
[TBL] [Abstract][Full Text] [Related]
12. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
13. BTK Inhibitors in Haematology: Beyond B Cell Malignancies.
Leitinger DE; Kaplan DZ
Transfus Med Rev; 2022 Oct; 36(4):239-245. PubMed ID: 36376164
[TBL] [Abstract][Full Text] [Related]
14. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
15. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
16. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
17. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
18. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Kozaki R; Vogler M; Walter HS; Jayne S; Dinsdale D; Siebert R; Dyer MJS; Yoshizawa T
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29690649
[TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
Wang X; Kokabee L; Kokabee M; Conklin DS
Front Cell Dev Biol; 2021; 9():668996. PubMed ID: 34307353
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]